EU Health Innovation Programs to Watch in 2026

Why European health innovators pay attention to EU programmes

For anyone developing medical devices, digital health tools, or biotech solutions in Europe, the European Union is the primary source of non‑dilutive funding, regulatory guidance, and market‑access support. The EU’s research and innovation framework aligns national priorities, pools talent across borders, and creates a single set of expectations for safety, data protection, and sustainability. Understanding which programmes are active, what they fund, and how they are administered helps innovators plan realistic project timelines, avoid duplicated effort, and position their solutions for later EU‑wide adoption.

How the EU innovation landscape is organised in 2026

The EU’s health‑focused funding sits at the intersection of three major structures:

• Horizon Europe – the €95 billion research and innovation programme that runs until 2027. Its clusters “Health” and “Digital, Industry and Space” contain most health‑related calls.
• European Innovation Partnership (EIP) on Active and Healthy Ageing – a network that runs thematic reference sites, test‑beds and co‑creation projects focused on ageing societies.
• EU Health Funding Instruments – stand‑alone budgets such as the EU4Health programme, the European Medicines Agency (EMA) Innovation Task Force, and the Digital Health Europe initiative.

Each structure has its own governance, application rhythm, and evaluation criteria. Some programmes are competitive grants; others are thematic partnerships that provide access to test environments, data sets, or regulatory advice.

Key programmes that will shape health innovation in 2026

Horizon Europe – Health Cluster (HEALTH)

The Health Cluster within Horizon Europe continues to be the biggest source of research funding for health technologies. In 2026, the cluster will focus on four main pillars:

• Personalised medicine and genomics – projects that develop biomarker‑driven therapies, gene‑editing platforms, or AI‑based diagnostic pipelines.
• Digital health and data infrastructure – funding for interoperable health‑IT systems, AI‑driven decision support, and secure data‑exchange frameworks that comply with the European Health Data Space (EHDS).
• Health crisis preparedness – rapid‑response calls for tools that improve pandemic monitoring, vaccine distribution logistics, and resilient supply chains.
• Societal challenges – solutions that address health inequities, chronic disease management, and the health impacts of climate change.

Typical grant sizes range from €2 million for a two‑year collaborative research project to €10 million for large‑scale demonstrators that involve multiple partners across EU member states.

EU4Health – The EU’s health‑system strengthening programme

EU4Health, launched in 2021 with a €5.1 billion budget, entered its second phase in 2024 and will run through 2027. While its initial focus was on pandemic preparedness, the programme now allocates a substantial share to innovative health‑system solutions:

• Digital transformation – funding for electronic health‑record (EHR) integration, telemedicine platforms, and cross‑border health data portals.
• Health workforce development – grants for training modules that upskill clinicians in AI‑assisted diagnostics and remote care.
• Patient‑centred care models – support for community‑based prevention programmes, chronic‑disease self‑management apps, and integrated care pathways.

EU4Health awards are typically delivered as action grants to public authorities, NGOs, or consortia that demonstrate clear public‑health impact. Budget lines are often earmarked for “pilot” or “scaling‑up” phases, making it a useful route for solutions that have cleared early research milestones.

EIP on Active and Healthy Ageing – Reference Sites and Test‑beds

The European Innovation Partnership on Active and Healthy Ageing (EIP‑AHA) continues to coordinate thematic reference sites that bring together municipalities, research institutes, and private firms. In 2026, three reference sites are receiving the most attention:

• Digital Ageing Solutions – platforms that combine wearables, AI analytics, and caregiver dashboards to monitor frailty and fall risk.
• Integrated Care Pathways for Dementia – cross‑sector pilots that link primary care, social services, and digital memory assessment tools.
• Nutrition and Physical Activity Promotion – community‑based programmes that use gamified apps to encourage healthy eating and exercise among seniors.

Participation is not competitive in the traditional grant sense; instead, sites invite partners to co‑create solutions, providing access to real‑world test environments and EU‑wide dissemination channels.

Digital Health Europe (DHE) – A joint EU‑Commission and EMA initiative

Digital Health Europe was created to accelerate the adoption of certified digital health technologies across the single market. Its 2026 priorities include:

• Facilitating conformity assessment for medical‑device software under the EU Medical Device Regulation (MDR) and In‑Vitro Diagnostic Regulation (IVDR).
• Supporting the establishment of “European Health‑IT Labs” that host sandbox environments for AI‑driven diagnostics.
• Funding cross‑border pilot projects that demonstrate interoperable telehealth services.

DHE offers two types of financial support: (1) a “fast‑track” grant of up to €500 000 for regulatory‑science projects, and (2) a “scale‑up” grant of up to €2 million for proven solutions ready for market entry.

EMA Innovation Task Force (ITF) – Regulatory advice for early‑stage developers

The EMA’s Innovation Task Force provides scientific advice to developers of medicines, advanced therapy medicinal products (ATMPs), and certain Class III medical devices. In 2026 the ITF is expanding its scope to include:

• AI‑based companion diagnostics that inform treatment choice.
• Cell‑based therapies that use gene‑editing tools.
• Hybrid products that combine a drug and a digital therapeutic.

Engagement with the ITF is free of charge, but slots are allocated on a first‑come, first‑served basis, and applicants must demonstrate a clear regulatory question and a realistic development plan.

How to choose the right programme for your project

Selecting a funding source begins with a realistic assessment of project maturity, partnership needs, and compliance requirements. The following decision matrix helps narrow options:

Project Stage	Key Needs	Best‑Fit EU Programme(s)
Concept / feasibility	Exploratory research, proof of concept, early data	Horizon Europe – HEALTH (SME‑focused calls)
Prototype / pilot	Clinical validation, regulatory pathway definition, test‑bed access	Digital Health Europe fast‑track; EMA ITF; EIP‑AHA test‑beds
Demonstration / scaling	Cross‑border rollout, health‑system integration, market‑ready certification	EU4Health action grants; DHE scale‑up; Horizon Europe large demonstrators
Policy impact / sustainability	Long‑term financing, health‑economics evaluation, public‑sector adoption	EU4Health health‑system strengthening; Horizon Europe societal challenges

Beyond stage alignment, consider the following practical factors:

• Consortium requirements – Horizon Europe mandates at least three independent legal entities from three EU countries. EU4Health is more flexible and can be awarded to a single public authority.
• Data protection obligations – Projects using patient data must comply with the GDPR and, from 2025 onward, the European Health Data Space rules. DHE labs provide built‑in compliance support.
• Intellectual property (IP) strategy – Horizon Europe adopts a “shared‑ownership” model for results, while EU4Health often allows full IP retention for the lead applicant.
• Time to award – EMA ITF advice can be secured within 3–4 months, whereas Horizon Europe calls may have a 12‑month evaluation cycle.

Practical steps to prepare a competitive application

Regardless of the programme, reviewers look for the same core elements: clear impact, robust methodology, and a realistic execution plan. The following checklist reduces the risk of common pitfalls.

1. Define the public‑health problem in EU terms

Link the problem to EU statistics (e.g., prevalence of diabetes in the EU‑27) and to policy documents such as the European Health Union strategy. Demonstrating alignment with EU priorities shows relevance.

2. Assemble a balanced consortium

Include at least one research institute, one industry partner, and one end‑user organization (hospital, health authority, or patient association). Verify that each partner can cover the “excellence, impact, and implementation” criteria used by most EU evaluators.

3. Build a realistic work‑package structure

Break the project into clear work packages (WP) with defined deliverables, milestones, and responsibilities. Use Gantt‑style timelines to illustrate feasibility within the programme’s funding period.

4. Address regulatory and data‑governance early

Identify the applicable regulatory pathway (MDR, IVDR, EMA, etc.) and outline a compliance roadmap. Include a data‑management plan that meets GDPR and EHDS requirements, even if the call does not explicitly require it.

5. Quantify expected impact

Provide numeric estimates where possible: reduction in hospital readmission rates, cost‑savings per patient, or carbon‑footprint reduction. Use existing EU health‑economics studies as benchmarks.

6. Prepare a strong dissemination plan

Outline how results will reach clinicians, policy makers, and patients across the EU. Mention open‑access publication, participation in EU conferences, and use of the EU’s Open Science Cloud where appropriate.

7. Budget transparently

Allocate costs to each work package, distinguishing between research, personnel, equipment, and indirect costs. Avoid “blanket” entries; reviewers often penalise vague budgeting.

Examples of successful projects and lessons learned

Several high‑profile initiatives illustrate how the programmes can be leveraged effectively.

Case 1 – AI‑assisted retinal screening (Horizon Europe)

A consortium of a German university hospital, a Dutch AI start‑up, and a French health‑data platform received €6 million in 2023 to develop an automated retinal image analysis tool for diabetic retinopathy. Key success factors included:

• Early engagement with the EMA ITF to clarify the MDR classification.
• Use of a cross‑border data set that complied with the EHDS framework, reducing data‑sharing delays.
• A clear plan for integration into existing national screening programmes, which satisfied the “impact” criterion of the call.

Case 2 – Tele‑rehabilitation for chronic obstructive pulmonary disease (EU4Health)

A public‑private partnership in Spain leveraged a €2 million EU4Health action grant to pilot a tele‑rehabilitation platform that combined remote spirometry, AI‑driven exercise coaching, and a patient‑portal. Lessons learned:

• Co‑design with patient associations improved usability and boosted adoption rates.
• Embedding the solution within the national health‑service IT architecture facilitated reimbursement discussions.
• Collecting real‑world outcomes (hospitalisation reduction) enabled a rapid scale‑up request for additional EU funding.

Case 3 – Digital Twin for elderly care coordination (EIP‑AHA)

A tri‑national reference site (Sweden, Italy, Portugal) created a “digital twin” model that simulated care pathways for frail older adults, allowing municipalities to test resource allocation before implementation. Funding came from EIP‑AHA thematic pilots. Key takeaways:

• Open‑source modelling tools reduced development costs.
• Regular workshops with local authorities kept the project grounded in real policy constraints.
• Results were published in an open‑access journal, increasing visibility for future EU calls.

Emerging trends that may affect funding priorities

Although the programmes listed above are already established, several broader trends are shaping the next round of calls.

Climate‑responsive health innovation

The EU Green Deal is prompting funders to prioritize solutions that reduce the carbon footprint of health care. Expect calls that explicitly request life‑cycle assessments, renewable‑energy‑compatible medical devices, or waste‑reduction strategies.

Integration of genomics with digital health

Projects that combine large‑scale genomic data with AI‑driven clinical decision support are increasingly viewed as high impact, especially when they address rare diseases or personalised oncology.

Strengthening supply‑chain resilience

Post‑COVID‑19, the EU is allocating more resources to technologies that improve traceability, local manufacturing, and rapid re‑deployment of essential medicines and devices.

Patient‑generated health data (PGHD)

Regulators are clarifying the role of data from wearables and home tests. Funding streams are emerging for platforms that can certify PGHD for clinical use while maintaining GDPR compliance.

Getting started: a practical roadmap for 2026

1. Map your solution to EU priorities. Review the EU Health Union strategy, the Horizon Europe work programme, and the EU4Health action plan to find the best fit.

2. Identify the appropriate call. Set alerts on the Funding & Tenders Portal and subscribe to newsletters of the European Commission’s Directorate‑General for Health and Food Safety (DG SANTE).

3. Build your consortium early. Reach out to potential partners through Euraxess, EIT Health, and national innovation agencies.

4. Prepare a pre‑proposal. Draft a one‑page concept note that outlines the problem, innovation, impact, and partners. Share it with the relevant EU programme contact for early feedback.

5. Secure regulatory advice. Book a slot with the EMA ITF or a national competent authority to clarify classification and conformity‑assessment routes.

6. Submit the full application. Follow the portal’s step‑by‑step guide, double‑check eligibility criteria, and upload all required annexes (budget, consortium agreement, data‑management plan).

7. Plan for post‑award management. Establish a project‑office structure, assign a grant‑manager, and set up regular reporting mechanisms to meet EU monitoring requirements.

By aligning each stage of development with the right EU programme, innovators can reduce financial risk, accelerate regulatory clearance, and increase the likelihood that their solution will be adopted across the European health system.